BrainsWay Ltd. (BWAY)
| Market Cap | 81.02M |
| Revenue (ttm) | 31.79M |
| Net Income (ttm) | -4.20M |
| Shares Out | 16.64M |
| EPS (ttm) | -0.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,416 |
| Open | 4.780 |
| Previous Close | 4.790 |
| Day's Range | 4.780 - 5.045 |
| 52-Week Range | 1.380 - 7.615 |
| Beta | 0.34 |
| Analysts | Buy |
| Price Target | 9.50 (+95.07%) |
| Earnings Date | May 15, 2024 |
About BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospi... [Read more]
Financial Performance
In 2023, BrainsWay's revenue was $31.79 million, an increase of 16.96% compared to the previous year's $27.18 million. Losses were -$4.20 million, -68.56% less than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BWAY stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 95.07% from the latest price.
News
BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease
Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms Clinical Data from Multiple Trials Showed Improvements in Both Motor and Non-Motor Symptoms
BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems
Katie's Way Provides Lifesaving Mental Health Treatment Nationally with a Focus on Servicemembers, Veterans, and their Families Katie's Way Provides Lifesaving Mental Health Treatment Nationally with ...
BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights
Generated Record Revenues with Robust 50% Year-over-Year Revenue Growth in Q4 2023; Generated Positive Quarterly Net Income
BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea
BURLINGTON, Mass. and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Reports Third Quarter 2023 Financial Results and Operational Highlights
Generated Robust 61% Year-over-Year Revenue Growth in Q3 2023 Nearing Breakeven Operating Income, Achieved Positive Adjusted EBITDA, with Cash Flow from Operations Exceeding $1 Million Conference Call...
BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression
Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Protocols Peer-reviewed Results Suggest Accelerated Deep TMS Outcomes Comparable to Standard Treatment Prot...
BrainsWay Broadens Access to Deep TMS™ for U.S. Military Service Members Through Expanded Partnership with Katie's Way Plus
Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems Provider of Mental Health Services with Focus on Military Community Orders 10 New Deep TMS™ Systems
BrainsWay Forges Strategic Partnership with Treatment Provider in Northeast U.S.
BURLINGTON, Mass. and JERUSALEM, Sept.
BrainsWay Further Expands Access to Deep TMS™ in Asia Pacific Region
Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan Multisystem Purchases by Unison Healthcare Group Increase Availability of Deep TMS™ in Taiwan
BrainsWay Reports Second Quarter 2023 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, Aug. 09, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...
BrainsWay Announces Publication of Three New Deep TMS Research Publications
New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research New Articles Enhance Understanding of Deep TMS Safety Profile and Survey Addiction Research
BrainsWay Accelerates International Expansion in India
Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™ Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™
BrainsWay Announces Significant Expansion in Western and Central U.S.
30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network 30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS Network
BrainsWay Announces Appointment of Ido Marom as CFO
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain d...
BrainsWay Launches Investigator Initiated Study (IIS) Program
Application Period Open for Data Collaboration and Equipment Loan Initiatives Application Period Open for Data Collaboration and Equipment Loan Initiatives
BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023
BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain...
BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023
BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...
BrainsWay Announces Appointment of Hadar Levy as CEO
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...